Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Delivery Systems

Categories

[Search within category]

Sealed Nanostraw Microdevices For Oral Drug Delivery

This invention is a nanostraw device that is built upon microdevice technology for oral drug delivery. It is the first example of a microdevice for oral drug delivery, with the drug sealed in by a semi-permeable membrane for (1) in-solution drug loading, and tunable drug release, (2) increased bioadhesion for prolonged drug exposure, and (3) protection of drug from outside biomolecules.

Nanowire-Coated Planar Microdevices For Transmucosal Drug Delivery

This invention describes a first-of-a-kind methodology using micro- and nanofabrication techniques to create polymeric microscale devices that are asymmetrically coated with nanowires. The nanowire coating provides an inherent high-throughput, low-waste drug loading mechanism, enhanced cytoadhesion, and may potentially interact with epithelial tissue to enhance drug permeation.

Omnidirectional MRI Catheter Resonator for Interventional Procedures

This invention describes an orientation-independent device that can create bright and highly localized signal enhancement during magnetic resonance imaging.

INFRARED FLUORESCENT PROTEASE REPORTERS FOR DEEP TISSUE IMAGING

This invention includes the design and use of protease imaging reporters which can be detected in deep tissue. These can be used to monitor the effects of protease inhibitors, proteases and protease mediated processes including apoptosis related to the treatment of disease states such as cancer.

A Novel Tumor Targeting Strategy for Cancer Chemotherapy

A novel small molecule tumor-activated prodrug technology that produces a therapeutic index multiplying effect, leading to reduced drug-associated toxicity and improved efficacy in cancer patients.

Modular Cell and Drug Delivery Cannula System

The use of cell transplantation in the brain shows great promise for the treatment of human neurological diseases, such as Parkinson's disease or stroke. Indeed, pre-clinical studies in animal models have shown significantly improved neurological function following cell grafting. However, in human trials the results have been considerably more variable. This has, in part, been attributed to concerns with poor cell distribution within the target area. A further issue that has arisen with the challenge of scaling up from animal models to humans is the increase in the number of transcortical penetrations required to deliver therapeutic agents. For surgical cell transplantation approaches, cell sedimentation and impaired graft viability are also concerns that need to be addressed to optimize the use of this therapeutic avenue.

Ultrasound Probe Holder for Guidance of Central Line Insertion Procedure

It is estimated that 750 thousand to 1 million of central line insertions are performed in the United States every year to deliver large doses of drugs, blood or nutrients to hospitalized patients.  This common surgical procedure involves insertion of a catheter in either the jugular or femoral veins and requires substantial dexterity and the use of both hands from the physician.  Studies have reported central line insertion failure and complication rates as high as 30% and 18.8% in the emergency medicine and critical care literature, respectively.  Serious complications due to improper central line insertion can include arterial puncture, pneumothorax, bleeding and air embolism.  The National Institute for Clinical Excellence recommends the use of ultrasound guidance during central line insertions, because it allows physicians to visualize blood vessels in real-time as they insert the catheter, and has been demonstrated to significantly decrease procedural failure and complication  rates.  However, ultrasound probes need to be held with a single hand, so a physician holding the probe while simultaneously preforming the procedure is seriously inconvenienced.

Targeted Intracellular Delivery of Nucleic Acids via Conjugation to Non-Lipid Carrier Molecules

Use of synthetic nucleic acids to manipulate gene function has become a powerful tool for both basic research and therapeutics.  Silencing disease targets by RNA interference is a promising approach to drug development, and various experimental RNA therapies are currently in clinical development by both small and large biotechnology companies.  miRNAs are also being developed for disease treatment and diagnosis.  However, lack of specifically targeted, efficient and safe vehicles for systemic delivery of small RNA payloads in vivo is a serious challenge.  Synthetic nucleic acids face a number of physiological barriers in the bloodstream, and their intracellular uptake is hampered by the fact that they are highly charged and have much larger molecular wieght than small-molecule drugs.  Current strategies to circumvent these problems includes local administration, chemical modifications of nucleic acids, viral delivery vectors, lipid-based delivery systems, polymer-based delivery systems and nanoparticle encapsulation.  These methods have serious flaws including toxicity, inummue effects, non-selectively and high cost of manufacturing.  Therefore, novel ways to deliver synthetic nucleic acids for use in humans and experimental animal models are sorely needed.

Novel Topical Composition to Provide Local Anesthesia and Facilitate Radial Artery Cannulation

UCSF cardiologists have developed a novel topical anesthetic composition that facilitates radial artery cannulation. This composition can be delivered either as a topical cream or through a transdermal patch and can be co-marketed with radial catheterization sheaths and cannulaes to increase product appeal to clinical users. In clinical trials, this novel composition causes local increase of the arterial diamter (by 25% or more for at least 30 minutes) and provides local anesthesia in the patient, without inducing undesirable systemic effects, thus enabling clinicians to insert radial arterial catheters with greater ease, reduce the risk of spasm, and reduce pain experienced by patients undergoing this procedure. 

IMPROVED SURGICAL SITE RADIOGRAPHIC MARKERS AND DELIVERY PLATFORM

Physicians at UCSF have invented an improved radiographic marker for use during open surgical procedures. The improved marker overcomes the migratory tendencies of surgical clips and gold markers seeds and is suitable for use with almost any tissue types. In addition, the marker can be used as a delivery platform for local chemical, thermal, or radiofrequency therapy to the operative site. One embodiment of this invention consists of an accessory which can place current commercially available markers and clips.

IMPROVED GENE TRANSFER AND WOUND HEALING

Brief description not available

Novel Pro-Drug Technology for Targeted Delivery of Therapeutic Agents

UCSF investigators have developed a novel targeted pro-drug technology that can selectively deliver a chemotherapeutic payload to cells in areas of high concentrations of endogenous free ferrous iron. The pro-drug can be conjugated to a variety of existing and novel pharmacologically active compounds to increase their therapeutic window and lower systemic toxicity by increasing the selectivity of their delivery. Applications include therapies for cancer and malaria and as imaging agents. 

NOVEL STEROL DERIVATIVES FOR SUPERIOR LIPOSOME STABILITY

BACKGROUND:   Liposomes have been used in many drug, nutritional, and cosmetic delivery applications due to their unique properties that mimic the phospholipid bilayer of cell membranes. In all of their applications, liposome stability is crucial for efficient delivery stable liposomes mimimize leakage and loss of the payload. Sterols such as cholesterol have been proven to to greatly improve liposome stabilization. Consequently, cholesterol is widely used in liposome formulations. Sterols, as phytosterols, are also used in a variety of nutritional products to reduce cholesterol levels in humans. UNMET NEED: When liposomes composed of free cholesterol and phospholipids are combined with biological fluids containing biological lipids and serum, cholesterol rapidly transfers out of the liposome into the biological lipids. This loss of cholesterol from the liposome results in decreased liposome stability and the subsequent leakage or loss of the encapsulated payload. Additionally, serum lipoproteins absorb free cholesterol, further increasing the rate of cholesterol loss from the liposome. Efforts to solve this problem have led to the development of water soluble sterol derivatives as well as hydrophobic sterols. However, neither have proven to be suitable for improving liposome stability. A new technology is needed that will allow liposomes with high amounts of sterols to remain stable when exposed to biological fluids.   SUMMARY: Scientists at UCSF have developed sterol derivatives that improve liposome stability both in vitro and in vivo. These derivatives can be incorporated into liposome formulations in the high amounts necessary to produce a stabilizing effect, and are resistant to transfer out of the liposome into biological fluid components. Cholesterol transfer out of a liposome in in a lipid laden environment typically occurs with a half-life of two hours, whereas the transfer of the UCSF sterol derivatives under the same conditions is undetectable after eight hours. Furthermore, liposomes containing UCSF sterol derivatives have demonstrated 80% less leakage in serum than liposomes containing free cholesterol.  As an example of an oncology application, UCSF sterol-containing liposomes encapsulating doxorubicin showed equivalent therapeutic effect when compared to DoxilTM in a mouse cancer model.  In an infectious disease application, UCSF sterol-containing liposomes encapsulating amphotericin B showed lower toxicity and improved activity against a panel of fungi compared to AmBisomeTM.

  • Go to Page: